BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V: BCT) ("BriaCell" or the "Company") a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, acknowledges that October is Breast Cancer Awareness Month, an annual campaign to increase awareness of the disease. Significant progress has been made in breast cancer support, prevention, detection, diagnosis, treatment, and care yet the estimated 43,600 breast cancer deaths per year in the U.S. still indicates a considerable need for more effective treatments.

Note from BriaCell's Chairman of the Board

October is Breast Cancer Awareness Month; yet, sadly, for millions touched by the pain and death of breast cancer, their Awareness is eternal. BriaCell's clinical aim to attack and destroy breast cancer tumors is also eternal, as we tirelessly advance our targeted immunotherapy clinical program and work with world-class cancer centers to recruit and treat patients.

Breast Cancer Awareness Month brings the awareness that BriaCell is not treating ‘subjects' or ‘n='. We are treating women – mothers, daughters, sisters, wives, and friends. Breast cancer kills 120 women each day in the U.S. alone. BriaCell's work has already demonstrated clinical benefit in trials thus far to patients who had failed multiple prior treatments.  There exists a unique opportunity to advance BriaCell's achievements on behalf of breast cancer patients, survivors and deceased, and their families.

BriaCell has emerged in 2021, with $57 million in cash as of July 31, 2021 and clinical advancements that support our mission. In June, we reported a 12.0 months overall survival benefit in advanced breast cancer patients, including 21.4 months of survival benefit for a woman with an eye-bulging tumor that was 100% resolved after our treatment. This particular woman was treated in our Phase I/IIa clinical trial in combination with immune checkpoint inhibitors, including pembrolizumab (KEYTRUDA ® ; manufactured by Merck & Co.) and, more recently, Incyte's retifanlimab (INCMGA00012) under a corporate collaboration with Incyte Corporation.

Most recently, we announced a securities buyback program to purchase up to 10% of common shares in the capital of the Company listed on the TSX Venture Exchange and the Nasdaq, and up to 10% of listed warrants on the Nasdaq, with the aim to further enhance value for our shareholders.

Finally, I encourage shareholders, prospective shareholders, and other stakeholders to contact me directly if you wish to further understand the strategy we have deployed to achieve our primary goals of accelerating BriaCell's remarkable clinical work while maximizing shareholder value.

Thank you for your continued support in our fight.

Sincere regards,

Jamieson Bondarenko
Director and Chairman of the Board
BriaCell Therapeutics Corp.

Breast Cancer: Facts & Statistics (U.S.)

Per the American Cancer Society 2021 report:

  • After skin cancer, breast cancer is the most frequently diagnosed cancer in women, with 281,550 women expected to be diagnosed with invasive breast cancer in 2021;
  • The average risk of a woman developing breast cancer sometime in her life is about 13%. This means there is a 1 in 8 chance she will develop breast cancer;
  • An estimated 43,600 women are expected to die from breast cancer in 2021, which would make breast cancer the second leading cause of cancer death in women after lung cancer.

About BriaCell Therapeutics Corp.

BriaCell is an immuno-oncology focused biotechnology company developing targeted and effective approaches for the management of cancer. More information is available at .

Safe Harbor

This press release contains "forward-looking statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will" "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on BriaCell's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading "Risks and Uncertainties" in the Company's most recent Management's Discussion and Analysis, under "Risks and Uncertainties" in the Company's other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under our profiles on SEDAR at and on EDGAR at . Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information

Company Contact:
William V. Williams, MD
President & CEO

Media Relations:
Jules Abraham
Director of Public Relations

Investor Relations Contact:

Primary Logo

News Provided by GlobeNewswire via QuoteMedia



Keep reading...Show less

European Commission Grants Expanded Marketing Authorization for Gilead's Biktarvy® for the Treatment of HIV in Pediatric Populations

EC Authorizes a Low-Dose Tablet for HIV Treatment in Virologically Suppressed Children at Least Two Years of Age and Weighing at Least 14 kg, Helping to Address a Critical Unmet Need –

– Biktarvy Provides an Effective Therapy Choice for a Diverse Range of People Living with HIV, including Children with Limited Treatment Options –

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Envisagenics Announces Research Collaboration with Bristol Myers Squibb

Collaboration will leverage Envisagenics' SpliceCore® AI platform for accelerated discovery and development of oncology therapeutic candidates

Envisagenics an Artificial Intelligence ("AI")-driven biotechnology company that delivers therapies for RNA splicing diseases, today announced a research collaboration agreement with Bristol Myers Squibb (NYSE: BMY). The multi-year collaboration will leverage Envisagenics' SpliceCore® AI platform to identify alternative splicing derived targets for therapeutic development to expand Bristol Myers Squibb's vast oncology pipeline. Envisagenics will receive an upfront payment and milestone payments based on development, regulatory, and commercial achievements.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Komo Reports Fiscal Year 2022 Financial Results

Komo Reports Fiscal Year 2022 Financial Results

Komo Plant Based Foods Inc. (CSE: YUM) (OTCQB: KOMOF) (FSE: 9HB0) ("Komo"), a premium plant-based food company, today reports financial results for the year ended July 31, 2022.

"We began our fiscal year as a new brand with a mission to make plant-based meals a staple on every dinner table by sharing our love for feel-good food that connects the people to the planet. Thanks to the strength of our team and the love of Komo products, we were successful in achieving sales growth of 935 percent over last year," says Komo founder and CEO William White. "The consistently strong retail sales of our products have allowed us to demonstrate to large retail chains that our products sell well and have repeat customers. We recently completed a national listing with Loblaws and we are in discussions with several other large national chains. As a result, we are anticipating continued significant revenue increases in 2023."

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
The Gummy Project Announces Grant of Stock Options

The Gummy Project Announces Grant of Stock Options

The Gummy Project Inc. (CSE: GUMY) (FSE: 0OS0) (OTCQB: GUMYD) ("GUMY" or the "Company") announces that it has issued a total of 2,300,000 stock options pursuant to its incentive stock option plan ("Plan") to consultants which vest on the grant date. Each option entitles the holder to subscribe for one common share of the Company for $0.06 for a period of 5 years, subject to the terms of the Plan. Over the past quarter, 1,664,800 options have lapsed or been cancelled.

About The Gummy Project

News Provided by Newsfile via QuoteMedia

Keep reading...Show less


Amgen (NASDAQ:AMGN) will host a webcast call for the investment community in conjunction with the World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) at 8:00 a.m. ET on Monday Dec. 5, 2022. David M. Reese M.D., executive vice president of Research and Development at Amgen, along with members of Amgen's R&D team, will discuss the Phase 1 data from AMG 133, a novel bispecific glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonist and glucagon-like peptide-1 (GLP-1) receptor agonist molecule.

The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Gilead and Arcus Biosciences Announce Positive Update on Joint TIGIT Program From Interim Analysis of ARC-7 Study in Non-small Cell Lung Cancer

Fourth Interim Analysis Shows Continued Clinically Meaningful Differentiation Across All Efficacy Measures, Including PFS, in Both Domvanalimab-Containing Arms Compared to the Anti-PD-1 Zimberelimab Monotherapy Arm in First-Line NSCLC Patients –

Data will be Presented on December 20, 2022 at the American Society of Clinical Oncology (ASCO) Monthly Plenary Series

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News